RÉSUMÉ
Objective To investigate the clinical use of low molecular weight heparin (LMWH) with thromboelastography (TEG)R time monitoring in malignant tumor patients, and guide clinical rational drug use. Methods 145 patients with malignant tumors were respectively first times and second times with low molecular weight heparin 4 h after venous blood determination of TEG R time and anti Xa activity, compare the effects of different doses of LMWH on TEG R time; the effects of different doses of LMWH against the activity of Xa; the correlation between the doses of LMWH at first time and TEG R time; the correlation between the doses of LMWH at first time and the activity of anti Xa; the correlation between TEG R time and the doses of LMWH at first time. Results Different doses of LMWH treatment had a significant effect on the TER G time (P < 0.05); no significant effect of different doses of LMWH against the activity of Xa; TEG R time with the first LMWH dose significantly correlated (P < 0.05); anti Xa activity and LMWH at the first time had no significant correlation between the dosage; no significant correlation with the anti Xa activity of TEG R time. Conclusion Using TEG R time to detect the clinical application of low molecular weight heparin is more sensitive and accurate compared with anti Xa activity detecting in patients with malignant tumor.